8-K Announcements
6Material company update
May 11, 2026·SEC
Material company update
Mar 26, 2026·SEC
Material company update
Mar 12, 2026·SEC
Enanta Pharmaceuticals, Inc.(ENTA)Earnings, Financials & Key Ratios
ENTA•NASDAQ
Price updated Jun 19, 2026
AboutEnanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.Show more
- Revenue$65M-3.4%
- EBITDA-$80M+32.8%
- Net Income-$82M+29.4%
- EPS (Diluted)-3.84+29.9%
- Gross Margin92.98%-7.0%
- EBITDA Margin-122.86%+30.4%
- Operating Margin-130.65%+27.4%
- Net Margin-125.36%+26.9%
- ROE-84.63%-26.0%
ENTA Key Insights
Enanta Pharmaceuticals, Inc. (ENTA) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
No significant strengths identified
✗Weaknesses
- ✗High debt to equity ratio of 3.1x
- ✗Profits declining 17.8% over 5 years
- ✗Weak Piotroski F-Score: 3/9
- ✗Negative free cash flow
- ✗Low quality earnings: Net income not backed by cash flow
- ✗Sales declining 11.8% over 5 years
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when ENTA posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
ENTA Price & Volume
Enanta Pharmaceuticals, Inc. (ENTA) stock price & volume — 10-year historical chart
Loading chart...
ENTA Growth Metrics
Enanta Pharmaceuticals, Inc. (ENTA) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-8.62%
5 Years-11.81%
3 Years-8.82%
TTM7.37%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM35.71%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM39.65%
Return on Capital
10 Years-11.41%
5 Years-31.87%
3 Years-33.8%
Last Year-30.96%
ENTA Recent Earnings
Enanta Pharmaceuticals, Inc. (ENTA) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 8/12 qtrs (67%)●Beat Revenue 6/12 qtrs (50%)
Q2 2026Latest
May 11, 2026Metric
Actual
Est
EPS
$0.45+2.2%
$0.46
Rev
$17M+0.8%
$17M
Q1 2026
Feb 9, 2026Metric
Actual
Est
EPS
$0.42+22.2%
$0.54
Rev
$19M+17.0%
$16M
Q4 2025
Nov 17, 2025Metric
Actual
Est
EPS
$0.87+23.0%
$1.13
Rev
$15M-5.3%
$16M
Q3 2025
Aug 11, 2025Metric
Actual
Est
EPS
$0.85+32.0%
$1.25
Rev
$18M+14.7%
$16M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 11, 2026 | $0.45vs $0.46+2.2% | $17Mvs $17M+0.8% |
| Q1 2026 | Feb 9, 2026 | $0.42vs $0.54+22.2% | $19Mvs $16M+17.0% |
| Q4 2025 | Nov 17, 2025 | $0.87vs $1.13+23.0% | $15Mvs $16M-5.3% |
| Q3 2025 | Aug 11, 2025 | $0.85vs $1.25+32.0% | $18Mvs $16M+14.7% |
Based on last 12 quarters of dataView full earnings history →
ENTA Peer Comparison
Enanta Pharmaceuticals, Inc. (ENTA) competitors in Vaccines and Infectious Disease — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 ACHV | 259.04M | 4.85 | -3.88 | -193.49% | 0.70 | |||
 AGIO | 2.03B | 34.16 | -4.80 | 48.03% | -6.4% | -34.11% | 0.05 | |
 ARQT | 3.28B | 26.21 | -201.62 | 91.34% | -0.57% | -1.41% | 0.03 | |
 PRTA | 467.51M | 8.93 | -1.97 | -92.84% | -260.92% | -49.88% | 0.05 | |
 FOLD | 4.55B | 14.49 | -164.85 | 20.05% | -4.27% | -12.02% | 1.76 | |
 RCUS | 2.45B | 24.31 | -7.39 | -4.26% | -156.36% | -68.97% | 0.16 | |
 IMVT | 7.26B | 35.34 | -12.76 | -68.16% | 0.00 | |||
 ALNY | 37.1B | 278.09 | 119.35 | 65.19% | 13.46% | 98.29% | 1.62 |
Compare ENTA vs Peers
Enanta Pharmaceuticals, Inc. (ENTA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ENTA Income Statement
Enanta Pharmaceuticals, Inc. (ENTA) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Sep'17 | Sep'18 | Sep'19 | Sep'20 | Sep'21 | Sep'22 | Sep'23 | Sep'24 | Sep'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 102.81M | 206.63M | 205.2M | 122.47M | 97.07M | 86.16M | 79.2M | 67.64M | 65.32M | 69.21M |
Revenue Growth % | 16.48% | 100.97% | -0.69% | -40.31% | -20.74% | -11.24% | -8.07% | -14.61% | -3.42% | 7.37% |
Cost of Goods Sold | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4.59M | 1.21M |
COGS % of Revenue | - | - | - | - | - | - | - | - | 7.02% | - |
Gross Profit | 102.81M▲ 0% | 206.63M▲ 101.0% | 205.2M▼ 0.7% | 122.47M▼ 40.3% | 97.07M▼ 20.7% | 86.16M▼ 11.2% | 79.2M▼ 8.1% | 67.64M▼ 14.6% | 60.74M▼ 10.2% | 68M▲ 0% |
Gross Margin % | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 92.98% | 98.25% |
Gross Profit Growth % | 16.48% | 100.97% | -0.69% | -40.31% | -20.74% | -11.24% | -8.07% | -14.61% | -10.2% | - |
Operating Expenses | 78.2M | 118.3M | 168.46M | 164.11M | 206.65M | 210M | 216.41M | 189.33M | 146.09M | 128.39M |
OpEx % of Revenue | 76.06% | 57.25% | 82.1% | 134% | 212.88% | 243.74% | 273.23% | 279.92% | 223.63% | - |
Selling, General & Admin | 20.75M | 23.44M | 26.25M | 27.36M | 32.54M | 45.48M | 52.89M | 57.85M | 43.93M | 38.28M |
SG&A % of Revenue | 20.18% | 11.34% | 12.79% | 22.34% | 33.52% | 52.79% | 66.77% | 85.53% | 67.25% | - |
Research & Development | 57.45M | 94.86M | 142.21M | 136.76M | 174.11M | 164.52M | 163.52M | 131.48M | 106.74M | 91.32M |
R&D % of Revenue | 55.88% | 45.91% | 69.31% | 111.66% | 179.36% | 190.95% | 206.46% | 194.39% | 163.4% | - |
Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -4.59M | -1000K |
Operating Income | 24.61M▲ 0% | 88.33M▲ 258.9% | 36.74M▼ 58.4% | -41.64M▼ 213.3% | -109.57M▼ 163.1% | -123.84M▼ 13.0% | -137.21M▼ 10.8% | -121.69M▲ 11.3% | -85.35M▲ 29.9% | -60.38M▲ 0% |
Operating Margin % | 23.94% | 42.75% | 17.9% | -34% | -112.88% | -143.74% | -173.23% | -179.92% | -130.65% | -87.24% |
Operating Income Growth % | -20.19% | 258.85% | -58.41% | -213.34% | -163.15% | -13.02% | -10.79% | 11.31% | 29.86% | - |
EBITDA | 26.75M | 90.85M | 40M | -37.99M | -106.24M | -120.87M | -134.84M | -119.36M | -80.26M | -55.45M |
EBITDA Margin % | 26.02% | 43.97% | 19.49% | -31.02% | -109.44% | -140.29% | -170.24% | -176.47% | -122.86% | -80.12% |
EBITDA Growth % | -17.69% | 239.6% | -55.97% | -195% | -179.61% | -13.77% | -11.55% | 11.48% | 32.76% | 43.96% |
D&A (Non-Cash Add-back) | 2.14M | 2.52M | 3.26M | 3.64M | 3.33M | 2.97M | 2.37M | 2.34M | 5.09M | 4.93M |
EBIT | 24.61M | 88.33M | 36.74M | -41.64M | -107.58M | -122.19M | -125.85M | -106.85M | -75.87M | -53.57M |
Net Interest Income | 2.49M | 4.85M | 8.82M | 6.47M | 2.02M | 1.57M | 6.21M | 3.83M | 1.8M | -1.51M |
Interest Income | 2.53M | 0 | 8.82M | 6.47M | 2.02M | 1.57M | 11.36M | 14.77M | 9.48M | 8.9M |
Interest Expense | 40K | 4.85M | 0 | 0 | 0 | 0 | 5.15M | 10.94M | 7.68M | 10.4M |
Other Income/Expense | 2.33M | 4.79M | 8.82M | 6.62M | 1.99M | 1.66M | 6.21M | 3.9M | 1.8M | -1.51M |
Pretax Income | 26.95M▲ 0% | 93.12M▲ 245.6% | 45.56M▼ 51.1% | -35.02M▼ 176.9% | -107.58M▼ 207.2% | -122.19M▼ 13.6% | -131M▼ 7.2% | -117.79M▲ 10.1% | -83.55M▲ 29.1% | -61.89M▲ 0% |
Pretax Margin % | 26.21% | 45.07% | 22.2% | -28.59% | -110.82% | -141.82% | -165.39% | -174.15% | -127.9% | -89.42% |
Income Tax | 9.24M | 21.16M | -826K | 1.15M | -28.58M | -433K | 2.82M | -1.74M | -1.66M | 92K |
Effective Tax Rate % | 34.28% | 22.73% | -1.81% | -3.28% | 26.57% | 0.35% | -2.15% | 1.48% | 1.99% | -0.15% |
Net Income | 17.71M▲ 0% | 71.96M▲ 306.3% | 46.38M▼ 35.5% | -36.17M▼ 178.0% | -79M▼ 118.4% | -121.75M▼ 54.1% | -133.82M▼ 9.9% | -116.05M▲ 13.3% | -81.89M▲ 29.4% | -61.98M▲ 0% |
Net Margin % | 17.23% | 34.82% | 22.6% | -29.53% | -81.38% | -141.31% | -168.95% | -171.58% | -125.36% | -89.56% |
Net Income Growth % | -18.26% | 306.3% | -35.54% | -177.98% | -118.41% | -54.13% | -9.91% | 13.28% | 29.43% | 35.71% |
Net Income (Continuing) | 17.71M | 71.96M | 46.38M | -36.17M | -79M | -121.75M | -133.82M | -116.05M | -81.89M | -61.98M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | 0.91▲ 0% | 3.48▲ 282.4% | 2.21▼ 36.5% | -1.81▼ 181.9% | -3.92▼ 116.6% | -5.91▼ 50.8% | -6.38▼ 8.0% | -5.48▲ 14.1% | -3.84▲ 29.9% | -2.15▲ 0% |
EPS Growth % | -19.47% | 282.42% | -36.49% | -181.9% | -116.57% | -50.77% | -7.95% | 14.11% | 29.93% | 39.65% |
EPS (Basic) | 0.93 | 3.48 | 2.37 | -1.81 | -3.92 | -5.91 | -6.38 | -5.48 | -3.84 | - |
Diluted Shares Outstanding | 19.41M | 20.65M | 20.97M | 19.94M | 20.17M | 20.6M | 20.97M | 21.16M | 21.34M | 28.89M |
Basic Shares Outstanding | 19.07M | 20.65M | 19.58M | 19.94M | 20.17M | 20.6M | 20.97M | 21.16M | 21.34M | 28.89M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
ENTA Balance Sheet
Enanta Pharmaceuticals, Inc. (ENTA) balance sheet — assets, liabilities & shareholders' equity
| Metric | Sep'17 | Sep'18 | Sep'19 | Sep'20 | Sep'21 | Sep'22 | Sep'23 | Sep'24 | Sep'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 237.82M | 380.39M | 401.85M | 436.84M | 319.02M | 311.71M | 422.79M | 299.85M | 204.34M | 178.41M |
Cash & Short-Term Investments | 223.67M | 308.73M | 335.24M | 386.65M | 244M | 249.23M | 369.91M | 248.19M | 188.86M | 163.77M |
Cash Only | 65.67M | 63.9M | 51.23M | 87.13M | 57.21M | 43.99M | 85.39M | 37.23M | 32.3M | 34.93M |
Short-Term Investments | 157.99M | 244.83M | 284.01M | 299.52M | 186.8M | 205.24M | 284.52M | 210.95M | 156.57M | 128.85M |
Accounts Receivable | 10.61M | 67.2M | 51.31M | 23.49M | 60.83M | 49.04M | 39.62M | 38.65M | 6.88M | 7.83M |
Days Sales Outstanding | 37.68 | 118.72 | 91.27 | 70.01 | 228.73 | 207.73 | 182.57 | 208.55 | 38.45 | 41.61 |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
Other Current Assets | 3.54M | 4.45M | 0 | 26.7M | 0 | 0 | 13.26M | 608K | 8.59M | 6.81M |
Total Non-Current Assets | 88.82M | 33.84M | 87.98M | 53.95M | 121.84M | 68.88M | 39.48M | 76.8M | 76.4M | 136.29M |
Property, Plant & Equipment | 8.05M | 8.37M | 10.93M | 15.62M | 10.65M | 29.75M | 34.71M | 73.35M | 72.94M | 69.55M |
Fixed Asset Turnover | 12.77x | 24.67x | 18.78x | 7.84x | 9.11x | 2.90x | 2.28x | 0.92x | 0.90x | 0.96x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 70.04M | 16.39M | 65.01M | 33.24M | 109.02M | 33.25M | 3.97M | 3.36M | 3.36M | 129.37M |
Other Non-Current Assets | 608K | 700K | 700K | 92K | 92K | 696K | 803K | 94K | 92K | 144K |
Total Assets | 326.64M▲ 0% | 414.23M▲ 26.8% | 489.83M▲ 18.3% | 490.79M▲ 0.2% | 440.86M▼ 10.2% | 380.59M▼ 13.7% | 462.27M▲ 21.5% | 376.65M▼ 18.5% | 280.73M▼ 25.5% | 314.7M▲ 0% |
Asset Turnover | 0.31x | 0.50x | 0.42x | 0.25x | 0.22x | 0.23x | 0.17x | 0.18x | 0.23x | 0.23x |
Asset Growth % | 16.13% | 26.82% | 18.25% | 0.2% | -10.17% | -13.67% | 21.46% | -18.52% | -25.47% | -58.04% |
Total Current Liabilities | 20.98M | 16.02M | 22.61M | 24.16M | 36.17M | 29.83M | 62.79M | 57.53M | 48.55M | 46.44M |
Accounts Payable | 3.71M | 4.75M | 6.69M | 5.74M | 9.54M | 6M | 4.1M | 8M | 1.95M | 4.36M |
Days Payables Outstanding | - | - | - | - | - | - | - | - | 155.04 | 886.31 |
Short-Term Debt | 0 | 0 | 0 | 4.26M | 0 | 0 | 0 | 34.46M | 30.71M | 35.22M |
Deferred Revenue (Current) | 9.3M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 9.22M | 0 | 0 | 9.38M | 16.34M | 14.5M | 35.08M | 0 | 0 | 6.86M |
Current Ratio | 11.33x | 23.74x | 17.77x | 18.08x | 8.82x | 10.45x | 6.73x | 5.21x | 4.21x | 3.84x |
Quick Ratio | 11.33x | 23.74x | 17.77x | 18.08x | 8.82x | 10.45x | 6.73x | 5.21x | 4.21x | 3.84x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | -844.7 |
Total Non-Current Liabilities | 3.98M | 4.52M | 4.73M | 11.05M | 5.26M | 29.43M | 182.75M | 190.3M | 167.46M | 151.67M |
Long-Term Debt | 0 | 0 | 0 | 1.48M | 1.51M | 1.42M | 0 | 136.13M | 112.44M | 98.62M |
Capital Lease Obligations | 379K | 293K | 200K | 3.84M | 1.13M | 22.37M | 21.24M | 53.94M | 54.76M | 216.97M |
Deferred Tax Liabilities | 1.18M | 1.79M | 1.75M | 4.66M | 2.07M | 5.18M | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 3.6M | 4.23M | 4.53M | 1.08M | 558K | 454K | 161.51M | 231K | 260K | 278K |
Total Liabilities | 24.96M | 20.55M | 27.34M | 35.21M | 41.43M | 59.26M | 245.54M | 247.84M | 216.01M | 198.12M |
Total Debt | 458K | 293K | 200K | 9.58M | 6.83M | 26.69M | 26.51M | 226.06M | 201.06M | 186.62M |
Net Debt | -65.22M | -63.61M | -51.03M | -77.55M | -50.37M | -17.31M | -58.88M | 188.82M | 168.76M | 151.69M |
Debt / Equity | 0.00x | 0.00x | 0.00x | 0.02x | 0.02x | 0.08x | 0.12x | 1.75x | 3.11x | 1.60x |
Debt / EBITDA | 0.02x | 0.00x | 0.01x | - | - | - | - | - | - | -3.37x |
Net Debt / EBITDA | -2.44x | -0.70x | -1.28x | - | - | - | - | - | - | -2.74x |
Interest Coverage | 615.35x | 18.20x | - | - | - | - | -24.45x | -9.77x | -9.88x | -5.15x |
Total Equity | 301.68M▲ 0% | 393.68M▲ 30.5% | 462.49M▲ 17.5% | 455.58M▼ 1.5% | 399.43M▼ 12.3% | 321.33M▼ 19.6% | 216.74M▼ 32.6% | 128.81M▼ 40.6% | 64.72M▼ 49.8% | 116.59M▲ 0% |
Equity Growth % | 11.76% | 30.5% | 17.48% | -1.49% | -12.33% | -19.55% | -32.55% | -40.57% | -49.76% | -58.67% |
Book Value per Share | 15.54 | 19.06 | 22.06 | 22.85 | 19.80 | 15.60 | 10.34 | 6.09 | 3.03 | 4.04 |
Total Shareholders' Equity | 301.68M | 393.68M | 462.49M | 455.58M | 399.43M | 321.33M | 216.74M | 128.81M | 64.72M | 116.59M |
Common Stock | 191K | 194K | 197K | 201K | 202K | 208K | 211K | 212K | 214K | 291K |
Retained Earnings | 45.36M | 117.36M | 163.74M | 127.57M | 48.58M | -73.18M | -207M | -323.04M | -404.93M | -429.96M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -112K | -398K | 146K | 844K | -382K | -3.72M | -1.17M | 302K | -339K | -734K |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
ENTA Cash Flow Statement
Enanta Pharmaceuticals, Inc. (ENTA) cash flow — operating, investing & free cash flow history
| Metric | Sep'17 | Sep'18 | Sep'19 | Sep'20 | Sep'21 | Sep'22 | Sep'23 | Sep'24 | Sep'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | 52.65M | 29.22M | 71.42M | 7.09M | -70M | -84.78M | -103.15M | -78.76M | -19.27M | -7.84M |
Operating CF Margin % | 51.21% | 14.14% | 34.8% | 5.79% | -72.11% | -98.4% | -130.24% | -116.45% | -29.5% | - |
Operating CF Growth % | 47.04% | -44.5% | 144.41% | -90.08% | -1087.53% | -21.12% | -21.67% | 23.64% | 75.53% | 333.4% |
Net Income | 17.71M | 71.96M | 46.38M | -36.17M | -79M | -121.75M | -133.82M | -116.05M | -81.89M | -61.98M |
Depreciation & Amortization | 2.14M | 2.52M | 3.26M | 3.64M | 3.33M | 2.97M | 2.37M | 2.34M | 5.09M | 4.95M |
Stock-Based Compensation | 13.07M | 15.85M | 19.23M | 19.57M | 20.99M | 26.97M | 28.22M | 26.8M | 18.57M | 12.02M |
Deferred Taxes | -1.65M | 1.86M | -3.14M | 10.61M | 345K | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | -581K | -1.17M | -5.8M | -3.47M | -1.98M | 242K | -7.95M | 1.02M | -946K | 2.42M |
Working Capital Changes | 21.97M | -61.79M | 11.49M | 12.9M | -13.69M | 6.79M | 8.02M | 7.13M | 39.91M | 34.76M |
Change in Receivables | 2.23M | -56.59M | 15.89M | 27.82M | -24.3M | 11.79M | 9.42M | 973K | 31.76M | 32.8M |
Change in Inventory | 18.63M | -6.42M | -6.48M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | 633K | 1.32M | 1.79M | -883K | 3.77M | -4.63M | -1.15M | -414K | -1.31M | 399K |
Cash from Investing | -4.57M | -35.4M | -86.66M | 19.83M | 36.99M | 54.9M | -53.58M | 58.23M | 40.35M | -59.54M |
Capital Expenditures | -2.51M | -2.98M | -5.42M | -1.45M | -750K | -2.13M | -9.06M | -17.95M | -12.9M | -1.77M |
CapEx % of Revenue | 2.44% | 1.44% | 2.64% | 1.18% | 0.77% | 2.47% | 11.44% | 26.54% | 19.74% | 2.56% |
Acquisitions | 0 | 0 | 86.66M | 0 | -37.74M | -54.9M | 44.52M | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | -2.07M | -32.42M | 0 | 0 | 37.74M | 54.9M | -44.52M | 0 | 0 | 0 |
Cash from Financing | 1.02M | 4.41M | 2.57M | 8.98M | 3.08M | 20.03M | 198.13M | -27.63M | -26.62M | 42.1M |
Debt Issued (Net) | -73K | -79K | -86K | 0 | 0 | 0 | 199.68M | -27.48M | -26.49M | -32.34M |
Equity Issued (Net) | 0 | 0 | 0 | 0 | 3.61M | 21.26M | 2.21M | 147K | 145K | 70.09M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 1.09M | 4.49M | 2.66M | 8.98M | -534K | -1.23M | -3.76M | -294K | -277K | 4.34M |
Net Change in Cash | 49.1M▲ 0% | -1.77M▼ 103.6% | -12.67M▼ 614.7% | 35.9M▲ 383.3% | -29.93M▼ 183.4% | -9.85M▲ 67.1% | 41.39M▲ 520.2% | -48.16M▼ 216.3% | -5.54M▲ 88.5% | -25.29M▲ 0% |
Free Cash Flow | 50.15M▲ 0% | 26.24M▼ 47.7% | 66M▲ 151.5% | 5.64M▼ 91.5% | -70.75M▼ 1353.7% | -86.91M▼ 22.8% | -112.21M▼ 29.1% | -96.71M▲ 13.8% | -32.17M▲ 66.7% | -9.61M▲ 0% |
FCF Margin % | 48.77% | 12.7% | 32.16% | 4.61% | -72.88% | -100.87% | -141.67% | -142.99% | -49.24% | -13.88% |
FCF Growth % | 61.39% | -47.68% | 151.54% | -91.45% | -1353.69% | -22.84% | -29.12% | 13.81% | 66.74% | 88.32% |
FCF per Share | 2.58 | 1.27 | 3.15 | 0.28 | -3.51 | -4.22 | -5.35 | -4.57 | -1.51 | -0.33 |
FCF Conversion (FCF/Net Income) | 2.97x | 0.41x | 1.54x | -0.20x | 0.89x | 0.70x | 0.77x | 0.68x | 0.24x | 0.16x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 1.99M | 11.71M | 8.79M | 3.31M |
Taxes Paid | 1.59M | 26.09M | 12.67M | 105K | 32K | 0 | 4.9M | 241K | 109K | 0 |
ENTA Key Ratios
Enanta Pharmaceuticals, Inc. (ENTA) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | 6.2% | 20.7% | 10.84% | -7.88% | -18.48% | -33.78% | -49.74% | -67.17% | -84.63% | -64.04% |
Return on Invested Capital (ROIC) | 7.53% | 23.39% | 7.43% | -7.91% | -22.61% | -28.44% | -44.56% | -38.39% | -23.23% | -17.66% |
Gross Margin | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 92.98% | 98.25% |
Net Margin | 17.23% | 34.82% | 22.6% | -29.53% | -81.38% | -141.31% | -168.95% | -171.58% | -125.36% | -89.56% |
Debt / Equity | 0.00x | 0.00x | 0.00x | 0.02x | 0.02x | 0.08x | 0.12x | 1.75x | 3.11x | 1.60x |
Interest Coverage | 615.35x | 18.20x | - | - | - | - | -24.45x | -9.77x | -9.88x | -5.15x |
FCF Conversion | 2.97x | 0.41x | 1.54x | -0.20x | 0.89x | 0.70x | 0.77x | 0.68x | 0.24x | 0.16x |
Revenue Growth | 16.48% | 100.97% | -0.69% | -40.31% | -20.74% | -11.24% | -8.07% | -14.61% | -3.42% | 7.37% |
Related:ENTA Dividend History·ENTA Revenue History·ENTA Price History·ENTA P/E History·ENTA Financial Ratios·ENTA Institutional Holders
ENTA SEC Filings & Documents
Enanta Pharmaceuticals, Inc. (ENTA) SEC filings — annual & quarterly reports (10-K, 10-Q)
ENTA Frequently Asked Questions
Enanta Pharmaceuticals, Inc. (ENTA) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Enanta Pharmaceuticals, Inc. (ENTA) reported $69.2M in revenue for fiscal year 2025. This represents a 65% increase from $41.9M in 2011.
Enanta Pharmaceuticals, Inc. (ENTA) saw revenue decline by 3.4% over the past year.
Enanta Pharmaceuticals, Inc. (ENTA) reported a net loss of $62.0M for fiscal year 2025.
Dividend & Returns
Enanta Pharmaceuticals, Inc. (ENTA) has a return on equity (ROE) of -84.6%. Negative ROE indicates the company is unprofitable.
Enanta Pharmaceuticals, Inc. (ENTA) had negative free cash flow of $9.6M in fiscal year 2025, likely due to heavy capital investments.